What is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a hormone released from the gastrointestinal tract. It participates in glucose-dependent insulin secretion, glucagon regulation, gastric emptying and signals involved in appetite. Medicines targeting GLP-1 receptors extend or modify some of these biological actions.

Are all GLP-1 medicines the same?

No. Some treatments act only at the GLP-1 receptor, whereas certain other medicines activate more than one receptor. Products also differ in available formulations, dosing schedules, indicated populations and local regulatory approvals.

What does research demonstrate?

Well-designed randomized controlled trials have evaluated outcomes such as changes in weight, glucose measures and adverse events in particular patient groups. Trial results depend on dose, duration and other factors. Comparing numbers from different trials directly can be misleading.

What about side effects?

Nausea, vomiting, diarrhea and constipation are among commonly reported adverse events for several treatments. Important contraindications and other precautions differ between products. A qualified healthcare professional should assess appropriateness, interactions and monitoring.

What can you check in your country?

Review the product name, formulation and intended indication in your local regulator's database. Having an online seller or an imported product does not establish lawful authorization. See our regional regulatory guide and treatment comparison.

Primary sources

STEP 1: semaglutide randomized trial · SURMOUNT-1: tirzepatide randomized trial

GLP1Asia educational content is not personal medical advice. This article was prepared for the platform preview and should receive qualified review before production launch.